About Nafithromycin:
- It is an antibiotic which has been developed with the support of "Biotechnology Industry Research Assistance Council" (BIRAC).
- It has been brought to market under the trade name "Miqnaf".
- It is the country's first indigenously developed antibiotic aimed at tackling Antimicrobial Resistance (AMR).
- This innovation is designed to treat Community-Acquired Bacterial Pneumonia (CABP).
- Nafithromycin’s efficacy stands out as it targets both typical and atypical pathogens, offering a potent solution where no new antibiotic in this class has been developed worldwide for over three decades.
- The antibiotic has minimal gastrointestinal side effects, no significant drug interactions, and remains unaffected by food, making it a versatile option for patients.
- It offers 10x Efficacy with Just 3 doses to Combat Drug-Resistant Pneumonia.
- The development of Nafithromycin represents 14 years of dedicated research and an investment of ₹500 crores, with clinical trials spanning the U.S., Europe, and India.
Key facts about Community-Acquired Bacterial Pneumonia
- It is one of the most common infectious diseases and an important cause of mortality and morbidity worldwide.
- Typical bacterial pathogens that cause CAP include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
